Abstract
NKG2D is a major activation receptor on natural killer (NK) cells and a unique receptor on Cd8 T cells and subsets of NKT and γδ T cells. NKG2D is generally absent on CD4 T cells. The ligand of NKG2D (NKG2D-L) is generally absent on normal tissues, but prevalently induced on tumors cells as a response to genomic insults. Due to the unique nature of the NKG2D/NKG2D-L axis, attentions and efforts are emerging to harness the power of NKG2D/NKG2D-L for cancer immunotherapy. To support this development, this chapter will cover the basic biology of the NKG2D/NKG2D-L system and strategies to target this axis for cancer immunotherapy.
Original language | English (US) |
---|---|
Title of host publication | NK Cells in Cancer Immunotherapy |
Subtitle of host publication | Successes and Challenges |
Publisher | Elsevier |
Pages | 83-95 |
Number of pages | 13 |
ISBN (Electronic) | 9780128226209 |
ISBN (Print) | 9780128226261 |
DOIs | |
State | Published - Jan 1 2022 |
Keywords
- ATM
- Cancer
- Immunoreceptor
- MICB
- NKG2D
- Signaling
ASJC Scopus subject areas
- General Agricultural and Biological Sciences
- General Biochemistry, Genetics and Molecular Biology